Dear Wisee,
Did you catch NEOT today? Here you have a company with a drug in Phase I. They release information on 5/11, I believe, about a successful trial in Phase I. Nothing happens. Then they somehow manage to get on CNBC and vrooom!
My point is: we have in Nortran, a company with more varied drugs, further along in one series of drugs, and equal or better in another, backing from LaRoche, cash, quality management, etc, etc, etc. -- all this stock needs is more coverage, which will come. When Nortran has a successful trial using LaRoche money -- I can't wait. I really feel this is not as speculative as NEOT at this point. Smart money will be looking for a home soon IMO.
I remain,
SOROS |
